1. Hims & Hers demonstrates rapid revenue/subscriber growth and improved cash flow, reflecting strong brand momentum; 2. Gross margins dipped due to lower-margin obesity products, but SG&A efficiency supports operating leverage; 3. Collaboration with Novo Nordisk and capital raise enhance expansion prospects, though reliance on GLP-1 drugs and competition pose risks. The stock is upgraded to Buy with caution due to volatility.